CSIMarket
 
Vaxcyte Inc   (PCVX)
Other Ticker:  
 
 


 
 PCVX $68.3100 $0.8900 1.32%

 Volume (M): 732   Open : 68.22    52 Wk Avg :  54.19

 
 PCVX $68.3100 $0.8900 1.32%

 Volume (M): 732   Open : 68.22    52 Wk Avg :  54.19




PCVX Today's High: $69.685 PCVX Shares One Week Perf: 0.99 %
PCVX Today's Low: $ 67.55 PCVX Shares 30 Day Performance: -15.72 %
Number of PCVX Shares Traded (M): 732 PCVX Share Price 52 Wk High: $ 82.04
Value of PCVX's Shares Traded (M$): $ 49,969 PCVX Share Price 52 Wk Avg: $54.19
Share Price at the Open: $68.22 PCVX's Share Price 52 Wk Low: $34.11



  News about Vaxcyte Inc's Stock Splits and Dividends

Vaxcyte, Inc. Raises $862.5 Million in Record-Breaking Public Offering, Propelling Vaccine Innovator to New Heights

Vaxcyte, Inc. Closes Highly Successful Public Offering, Raising $862.5 Million to Advance Breakthrough Vaccines
SAN CARLOS, Calif., Feb. 02, 2024 - Vaxcyte, Inc., a pioneering vaccine innovation company, has recently concluded its underwritten public offering, resulting in the successful issuance of over 12 million shares of common stock along with pre-funded warrants. This oversubscribed offering, oversaw by the clinical-stage company, has raised approximately $862.5 million in aggregate gross proceeds. With an aim to engineer high-fidelity vaccines that combat bacterial diseases, Vaxcyte continues to make significant strides in revolutionizing the vaccine landscape.
This remarkable achievement marks a substantial increase from Vaxcyte's previous public offering, where the company expected to raise $750 million. The successful completion of this latest offering demonstrates the confidence investors have in Vaxcyte's vision, and their belief in the company's potential to shape the future of immunization against bacterial diseases.
The impact of this news on shareholders has been overwhelmingly positive. As of the time of writing this article, Vaxcyte Inc's share price stands at an impressive $75.53, reflecting a remarkable increase of 66% from the previous year. This surge in share value not only rewards existing shareholders but also attracts new investors interested in getting a piece of the promising vaccine innovation market.

Vaxcyte Announces Pricing of Public Offering to Support Advances in Bacterial Disease Vaccines


In a significant move towards advancing the fight against bacterial diseases, Vaxcyte, Inc. (Nasdaq: PCVX), a leading vaccine innovation company, has announced the pricing of its underwritten public offering of common stock and pre-funded warrants. The offering aims to raise approximately $750.0 million in gross proceeds, which will be crucial in furthering Vaxcyte's efforts to engineer high-fidelity vaccines to protect against the consequences of bacterial diseases.
Vaxcyte's offering comprises 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock. The shares of common stock are being offered at a public offering price of $64.00 per share, while the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant, with an exercise price of $0.001 per share. All the shares of common stock and pre-funded warrants will be offered by Vaxcyte, with the underwriters retaining a 30-day option to purchase up to an additional 1,757,812 shares of common stock.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com